Pixantrone clinical trials
Includes 1 study of Pixantrone dimaleate.
How each study uses pixantrone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 10 May 2012 · Pixuvri · EMEA/H/C/002055 (EMA; as pixantrone dimaleate; now expired)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 4
CTI BioPharma (8) · The Lymphoma Academic Research Organisation (1) · Johannes Gutenberg University Mainz (1) · Anne Beaven, MD (1) · Alliance for Clinical Trials in Oncology (1)
Often tested with
Tested in the same studies.
Rituximab (6) · Fludarabine (2) · Obinutuzumab (1) · Bendamustine (1) · Cyclophosphamide (1) · Vincristine (1) · Prednisone (1) · Dexamethasone (1)
Studies
Open first, then newest update. How each study uses pixantrone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin LymphomaCompletedPhase 2The Lymphoma Academic Research OrganisationNCT03458260Written as PixantroneHow we know
- Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic ImpairmentWithdrawnPhase 1CTI BioPharmaNCT01632436Written as PixantroneHow we know
- Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)CompletedPhase 1/2CTI BioPharmaNCT00106600Written as Pixantrone IV infusionHow we know
- GOAL: GA101 Plus Pixantrone for Relapsed Aggressive LymphomaCompletedPhase 2Johannes Gutenberg University MainzNCT02499003Written as Obinutuzumab and PixantroneHow we know
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantCompletedPhase 3CTI BioPharmaNCT01321541Written as Pixantrone + RituximabHow we know
- Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLWithdrawnPhase 3CTI BioPharmaNCT00577161Written as fludarabine, rituximab, pixantroneHow we know
- IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaCompletedPhase 1Anne Beaven, MDNCT01491841Written as Bendamustine + Rituximab + PixantroneHow we know
- BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)CompletedPhase 3CTI BioPharmaNCT00088530Written as pixantrone, cyclophosphamide, vincristine, rituximab, prednisoneHow we know
- Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory CancerWithdrawnPhase 1CTI BioPharmaNCT02800889Written as PixantroneHow we know
- Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT01086605Written as pixantrone dimaleateHow we know
- Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's LymphomaCompletedPhase 1CTI BioPharmaNCT00060684Written as Pixantrone (BBR 2778)How we know
- Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's LymphomaTerminatedPhase 3CTI BioPharmaNCT00060671Written as Pixantrone (BBR 2778)How we know
Given beside what is tested · 1 — pixantrone is usual care or a partner of the new treatment
Codes
What other systems call pixantrone · ClinicalTrials.gg INT003780
- MeSH (NLM) C086548pixantroneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) F5SXN2KNMRPIXANTRONEConfirmed FDA, NLM, Wikidata
- Wikidata Q7199690pixantroneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C26663PixantroneOne source FDA
- DrugBank DB06193One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C086548 | pixantrone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | F5SXN2KNMR | PIXANTRONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7199690 | pixantrone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C26663 | Pixantrone | One source FDA |
| DrugBank | DB06193 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.